Related references
Note: Only part of the references are listed.Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease
Alessandro Ghelardi et al.
VACCINES (2021)
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study
Elmar A. Joura et al.
VACCINE (2021)
World Health Organization call for action to eliminate cervical cancer globally
Murat Gultekin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Marc Arbyn et al.
LANCET GLOBAL HEALTH (2020)
Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women
George Valasoulis et al.
CANCERS (2020)
Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women A Systematic Review and Meta-analysis
Katie Lichter et al.
OBSTETRICS AND GYNECOLOGY (2020)
HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)
Andrea Ciavattini et al.
VACCINES (2020)
Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison
Giorgio Bogani et al.
VACCINES (2020)
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
Susanne K. Kjaer et al.
ECLINICALMEDICINE (2020)
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
Daron G. Ferris et al.
PAPILLOMAVIRUS RESEARCH (2020)
The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018-2019)
Paolo Bonanni et al.
EXPERT REVIEW OF VACCINES (2020)
Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy
Elmar A. Joura et al.
EUROPEAN JOURNAL OF CANCER (2019)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Melanie Drolet et al.
LANCET (2019)
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Elissa Meites et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?
Alex Vorsters et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies
Matti Lehtinen et al.
EXPERT REVIEW OF VACCINES (2019)
Epidemiology and burden of HPV-related disease
Beatriz Serrano et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2018)
Human Papillomavirus Prophylactic Vaccination improves reproductive outcome in infertile patients with HPV semen infection: a retrospective study
Andrea Garolla et al.
SCIENTIFIC REPORTS (2018)
SPERANZA project: HPV vaccination after treatment for CIN2+
Alessandro Ghelardi et al.
GYNECOLOGIC ONCOLOGY (2018)
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
Marc Arbyn et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations
VACCINE (2017)
Natural History of HPV Infection across the Lifespan: Role of Viral Latency
Patti E. Gravitt et al.
VIRUSES-BASEL (2017)
Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55years of age
Tino F. Schwarz et al.
CANCER MEDICINE (2017)
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial
Suzanne M. Garland et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study
Eva Herweijer et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study
S. Rachel Skinner et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Organization and quality of HPV vaccination programs in Europe
K. Miriam Elfstrom et al.
VACCINE (2015)
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
S. Rachel Skinner et al.
LANCET (2014)
Long-term efficacy and safety of human papillomavirus vaccination
Rosa De Vincenzo et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2014)
Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of GardasilTM in Adult Women
Joaquin Luna et al.
PLOS ONE (2013)
Updating the Natural History of Human Papillomavirus and Anogenital Cancers
Anna-Barbara Moscicki et al.
VACCINE (2012)
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
Elmar A. Joura et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
Sven-Eric Olsson et al.
HUMAN VACCINES (2009)
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
Nubia Munoz et al.
LANCET (2009)
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:: a meta-analysis
Silvia de Sanjose et al.
LANCET INFECTIOUS DISEASES (2007)
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica
R Herrero et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Share Paper
